Prenuvo is a real screening tool that produces real findings. It also sits in a category where the marketing runs ahead of the medical consensus on population-wide value, which makes the worth-it question harder than it looks.
The answer turns on your risk profile and on one number most buyers never estimate: the probability that the scan finds something benign that still takes months to rule out.
Public litigation
Prenuvo faces an open medical malpractice / negligence suit in New York (filed September 2024) alleging a radiologist missed stroke-related findings on a whole-body MRI. These are allegations, not findings — Washington Post.
The cost math
Priced against the alternatives that answer some version of the same question. Note the fifth row in particular — it is the comparison most buyers never make.
| Option | Cost |
|---|---|
| Prenuvo torso scan | ~$999 |
| Prenuvo whole-body scan | ~$2,499 |
| Realistic all-in with any follow-up workup | $2,499–$3,000+ |
| Ezra whole-body scan | ~$1,000–$2,500 |
| Single-region MRI, cash-pay at an imaging center | $400–$1,500 |
| Coronary CT calcium score, cash-pay | $100–$500 |
| Galleri multi-cancer blood test | Typically ~$950 |
| Follow-up imaging or biopsy after a finding | Insurance-billed; deductible and copays apply |
A single-region cash-pay MRI at a hospital or independent imaging center runs $400–$1,500 and requires a physician order — and Fountain Life bundles the same imaging into a much broader concierge program at $19,500+/yr. If you have a specific anatomical question — a persistent symptom, a known area of concern — that is a much cheaper way to answer it, and it is the route a physician would typically recommend first.
The whole-body price buys breadth in the absence of a specific question. That is precisely the use case the screening debate is about, and it is why the cost math cannot be settled on price alone. A $2,499 scan that finds a treatable cancer early is the best money you will ever spend. The same scan that finds a benign nodule and generates four months of workup has a real negative cost, financial and otherwise. Both outcomes are common; which one you get is mostly determined by your pre-test probability.
When Prenuvo is worth it
- Family history of cancer. Especially early-onset cancers or multiple first-degree relatives with the same type. Higher pre-test probability raises the yield of any screening test and shifts the balance of true positives to false ones.
- Known genetic risk markers. BRCA, Lynch syndrome, Li-Fraumeni, and other inherited cancer syndromes. Screening cadence matters more in these populations, and imaging becomes a legitimate tool — though a physician may direct you toward targeted surveillance rather than a broad scan, which is often better and sometimes insurance-covered.
- A specific concern that standard workup has not resolved. Persistent symptoms without a diagnosis, or a structural question a physician wants answered. This is closer to diagnosis than screening, and the yield is correspondingly higher.
- You want the fullest available imaging and can absorb the downstream cost. If the price is marginal to your finances and you have thought through what an ambiguous finding would mean for the next several months, the scan delivers exactly what it advertises.
When Prenuvo is not worth it
- You are average-risk and asymptomatic. Major medical societies do not recommend whole-body MRI in this population. The base rate of actionable findings is low relative to the rate of incidental ones, which is the guideline position in one sentence.
- You have a specific anatomical question. A single-region MRI at $400–$1,500, ordered by a physician, answers it for a fraction of the price — and may be insurance-covered where a screening scan never is.
- You cannot absorb follow-up costs. A finding triggers a workup at an outside facility, billed through insurance with deductible exposure and copays. Budget for that possibility before booking, not after.
- You are skipping guideline-recommended screening. A whole-body scan does not replace colonoscopy, mammography, or a lipid panel. Those have population-level mortality evidence behind them; this does not. If the $2,499 would come out of the budget for screening that is proven, the substitution is backwards.
What would change the answer
- A genetic test result. A positive BRCA, Lynch, or similar finding changes the pre-test probability enough to change the recommendation — usually toward surveillance imaging, sometimes toward this scan, and often toward something a physician orders rather than something you buy.
- A new first-degree relative diagnosis. Particularly an early-onset one. This is the most common real-world event that moves someone from average-risk to a category where imaging is defensible.
- A persistent symptom. Symptoms move the question from screening to diagnosis, where imaging yield is much higher — and where a physician-ordered study of the relevant region is usually the right first step, not a whole-body scan.
- Your tolerance for ambiguity. This one is personal and easy to underweight. If an unresolved finding would occupy your thoughts for months, that cost is real and belongs in the decision alongside the $2,499.
The Verdict
Yes if you have a family history of cancer, a known genetic risk marker, or a specific concern that imaging would resolve. Yes if you want the fullest available imaging, can absorb both the scan and any follow-up workup, and understand what a clean result does and does not rule out. No for average-risk asymptomatic adults, where major medical societies do not recommend whole-body MRI and the rate of benign findings requiring follow-up can exceed the rate of actionable ones.
The technology is not the question — MRI is safe and the scans are real. The question is whether your pre-test probability is high enough that the findings will be more useful than they are unsettling. For people with genuine elevated risk, it usually is. For average-risk asymptomatic adults, the guideline position exists for good reasons, and the same money spent on proven screening, a broad biomarker panel, or a physician relationship has better evidence behind it.
Frequently Asked Questions
Is Prenuvo worth $2,499?
For people with a family history of cancer, known genetic risk, or a specific concern worth imaging, yes — the pre-test probability of an actionable finding is high enough to justify the cost. For average-risk asymptomatic adults, the rate of actionable findings is low and the rate of benign findings requiring follow-up is meaningful. The answer depends on your risk profile, not on the pitch.
Does the medical establishment recommend it?
No, not for asymptomatic average-risk adults. Major medical societies do not currently recommend whole-body MRI screening in that population, largely because of incidental-finding rates and the absence of population-level mortality benefit data. Individual risk profiles change the calculation; the guideline position is about populations, not about you specifically.
Is it worth it if I have a family history of cancer?
The clinical case is stronger. Multiple first-degree relatives or a known marker such as BRCA raises pre-test probability, which raises the yield of any screening test. Discuss modality first, though — targeted surveillance for a specific inherited risk is often more appropriate than a broad scan, and sometimes it is covered by insurance where a whole-body scan is not.
Is it better than a Galleri blood test?
They answer different questions. Galleri is a blood-based multi-cancer early detection test looking for cancer-associated DNA fragments, at roughly $950. Prenuvo is imaging looking for structural findings. Different sensitivities, different false-positive profiles, different price points. Neither replaces the other, and neither replaces guideline-recommended screening such as colonoscopy or mammography.
What do people most often regret?
The incidental-finding spiral — months of repeat imaging, specialist visits, and low-grade anxiety over something that turned out to be benign. That is a known and expected consequence of screening this broadly, not a failure of the scan. The second regret is buying a whole-body scan when a single-region study at $400–$1,500 would have answered the actual question.
What are the risks of a scan?
MRI itself is safe and involves no radiation. The downsides are downstream: incidental findings that trigger unnecessary workups, false positives leading to biopsies, and false negatives creating a false sense of security. A clean scan rules out what MRI can see at that moment, not cancer generally.